Literature DB >> 30777879

MCL1 and DEDD Promote Urothelial Carcinoma Progression.

Jonathan E Rosenberg1,2, William C Hahn3,4,5, Andrew L Hong6,7,4, Jennifer L Guerriero7, Mihir B Doshi4, Bryan D Kynnap7, Won Jun Kim7, Anna C Schinzel7, Rebecca Modiste7, Amy J Schlauch7, Rosalyn M Adam6, David J Kwiatkowski7,5, Rameen Beroukhim7,4, Anthony Letai7.   

Abstract

Focal amplification of chromosome 1q23.3 in patients with advanced primary or relapsed urothelial carcinomas is associated with poor survival. We interrogated chromosome 1q23.3 and the nearby focal amplicon 1q21.3, as both are associated with increased lymph node disease in patients with urothelial carcinoma. Specifically, we assessed whether the oncogene MCL1 that resides in 1q21.3 and the genes that reside in the 1q23.3 amplicon were required for the proliferation or survival of urothelial carcinoma. We observed that suppressing MCL1 or the death effector domain-containing protein (DEDD) in the cells that harbor amplifications of 1q21.3 or 1q23.3, respectively, inhibited cell proliferation. We also found that overexpression of MCL1 or DEDD increased anchorage independence growth in vitro and increased experimental metastasis in vivo in the nonamplified urothelial carcinoma cell line, RT112. The expression of MCL1 confers resistance to a range of apoptosis inducers, while the expression of DEDD led to resistance to TNFα-induced apoptosis. These observations identify MCL1 and DEDD as genes that contribute to aggressive urothelial carcinoma. IMPLICATIONS: These studies identify MCL1 and DEDD as genes that contribute to aggressive urothelial carcinomas. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30777879      PMCID: PMC6548646          DOI: 10.1158/1541-7786.MCR-18-0963

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  40 in total

1.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

Authors:  J P Stein; G Lieskovsky; R Cote; S Groshen; A C Feng; S Boyd; E Skinner; B Bochner; D Thangathurai; M Mikhail; D Raghavan; D G Skinner
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

2.  Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma.

Authors:  M Höglund; T Säll; S Heim; F Mitelman; N Mandahl; I Fadl-Elmula
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

3.  Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas.

Authors:  C J Marshall; L M Franks; A W Carbonell
Journal:  J Natl Cancer Inst       Date:  1977-06       Impact factor: 13.506

4.  Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.

Authors:  Markus Riester; Lillian Werner; Joaquim Bellmunt; Shamini Selvarajah; Elizabeth A Guancial; Barbara A Weir; Edward C Stack; Rachel S Park; Robert O'Brien; Fabio A B Schutz; Toni K Choueiri; Sabina Signoretti; Josep Lloreta; Luigi Marchionni; Enrique Gallardo; Federico Rojo; Denise I Garcia; Yvonne Chekaluk; David J Kwiatkowski; Bernard H Bochner; William C Hahn; Azra H Ligon; Justine A Barletta; Massimo Loda; David M Berman; Philip W Kantoff; Franziska Michor; Jonathan E Rosenberg
Journal:  Clin Cancer Res       Date:  2014-01-31       Impact factor: 12.531

5.  Chromosomal aberrations associated with invasion in papillary superficial bladder cancer.

Authors:  R Simon; H Bürger; C Brinkschmidt; W Böcker; L Hertle; H J Terpe
Journal:  J Pathol       Date:  1998-08       Impact factor: 7.996

6.  DEDD, a novel death effector domain-containing protein, targeted to the nucleolus.

Authors:  A H Stegh; O Schickling; A Ehret; C Scaffidi; C Peterhänsel; T G Hofmann; I Grummt; P H Krammer; M E Peter
Journal:  EMBO J       Date:  1998-10-15       Impact factor: 11.598

7.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

8.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers.

Authors:  Craig H Mermel; Steven E Schumacher; Barbara Hill; Matthew L Meyerson; Rameen Beroukhim; Gad Getz
Journal:  Genome Biol       Date:  2011-04-28       Impact factor: 13.583

9.  Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.

Authors:  Padmanee Sharma; Margaret K Callahan; Petri Bono; Joseph Kim; Pavlina Spiliopoulou; Emiliano Calvo; Rathi N Pillai; Patrick A Ott; Filippo de Braud; Michael Morse; Dung T Le; Dirk Jaeger; Emily Chan; Chris Harbison; Chen-Sheng Lin; Marina Tschaika; Alex Azrilevich; Jonathan E Rosenberg
Journal:  Lancet Oncol       Date:  2016-10-09       Impact factor: 41.316

10.  A role for PVRL4-driven cell-cell interactions in tumorigenesis.

Authors:  Natalya N Pavlova; Christian Pallasch; Andrew E H Elia; Christian J Braun; Thomas F Westbrook; Michael Hemann; Stephen J Elledge
Journal:  Elife       Date:  2013-04-30       Impact factor: 8.140

View more
  2 in total

1.  Virus-mediated inactivation of anti-apoptotic Bcl-2 family members promotes Gasdermin-E-dependent pyroptosis in barrier epithelial cells.

Authors:  Megan H Orzalli; Aleksandra Prochera; Laurellee Payne; Avi Smith; Jonathan A Garlick; Jonathan C Kagan
Journal:  Immunity       Date:  2021-05-11       Impact factor: 43.474

Review 2.  Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options.

Authors:  Xiaowei Wu; Qingyu Luo; Zhihua Liu
Journal:  Cell Death Dis       Date:  2020-07-22       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.